A Surbiton couple is backing a UK-wide campaign to raise awareness of a rare form of epilepsy that affects their daughter. Jennifer and Tom Allen's nine-year-old daughter, Beth, has Dravet Syndrome.

The company has already secured approval for Fintepla in treating Dravet syndrome and Lennox-Gastaut syndrome.

A Surbiton couple, whose 9 year-old daughter has Dravet Syndrome, a rare, life-limiting, form of epilepsy, are backing a ...

A little baby suffering a seizure is an incredibly distressing event for a family. Epilepsy is the most common neurological disorder in children and it takes the form of recurring seizures. But ...

UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...

It’s mind-blowing what used to set them off." Faith had her first seizure at five months old and was diagnosed with Dravet Syndrome at 15 months after repeated emergency hospital visits.

The Stanley Brothers created Charlotte's Web, the CBD supplement that’s worked wonders on seizures. Now they are developing ...

Dr Ray O’Connor takes a look at the latest clinical articles on the subject of epilepsy, a common neurological disease that affects one to two per cent of the general population ...

UCB has shared promising results from a late-stage study of fenfluramine in patients with an ultra-rare form of epilepsy. The ...

A late-stage study has shown promising results for the effectiveness of fenfluramine in people with an ultra-rare form of epilepsy - CDKL5 deficiency disorder (CDD).

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...